WarrenDavidShlomchikMD

Oncology • Pittsburgh, PA

Hematologic Oncology

Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine

Join to view full profile

Dr. Shlomchik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shlomchik's full profile

Already have an account?

Office
5115 Centre Avenue
BST E1552
Pittsburgh, PA 15232

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1993 - 1997
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989

Certifications & Licensure

PA State Medical License 1993 - 2026
CT State Medical License 2000 - 2015
NY State Medical License 1991 - 1994
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD Start of enrollment: 2009 Dec 17
Terminated
Phase 2
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Start of enrollment: 2015 Feb 03
ACTIVE_NOT_RECRUITING
PHASE2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2019 Nov 19
RECRUITING
PHASE2

Publications & Presentations

PubMed

1 citations
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.
Kai Zhao, Jieqing Zhu, Sarah Rosenberger, Meng Zhou, Warren D Shlomchik
Blood Advances. 2025-01-14
Maintenance strategies for relapse prevention and treatment.
Emily Geramita, Jing-Zhou Hou, Warren D Shlomchik, Sawa Ito
Hematology. American Society of Hematology. Education Program. 2024-12-06
Natalizumab for GVHD: too little or too late?
Kevin Quann, Faruk Sacirbegovic, Warren D Shlomchik
Blood Advances. 2023-09-12

Lectures

The Making of Memory
60th American Society of Hematology Annual Meeting - 12/1/2018
CD8+ Effector T Cell Migration into the Bone Marrow of Transplanted Mice: Influence of Gvhd, Leukemia Cells and Variable Dependence on Chemokine Receptors
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Novel Transplant Approach Improves the Odds for Leukemia PatientsJanuary 10th, 2022

Grant Support

Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell TransplantationUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2028
Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell TransplantationUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2028
Graft-versus-Host Disease: Local Maintenance by Tissue Resident Progenitor T cellsUNIVERSITY OF PITTSBURGH AT PITTSBURGH2018–2028
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effectUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2025
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effectUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2025
Leukemia Stem Cells: Essential Targets For GVL And Mediators Of Gvl-ResistanceNational Cancer Institute2009–2012
Role Of Tissue Antigen Presenting Cells In GVHDNational Heart, Lung, And Blood Institute2011
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2010
Dendritic Cell Subsets And Paths Of Maturation In Graft-Vs.-Host Disease (GVHD)National Heart, Lung, And Blood Institute2007–2010
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2006–2009
Graft Versus Leukemia Against Murine Chronic Phase &Blast Crisis CMLNational Cancer Institute2007
Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Heart, Lung, And Blood Institute2006
GVL Against Murine Chronic Phase And Blast Crisis CMLNational Cancer Institute2003–2006
Novel Immunotoxins For Depletion Of Dendritic CellsNational Heart, Lung, And Blood Institute2005
Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1999–2002
Pathogenic Mechanisms Of GVD In Murine ModelNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000
Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1998